DeuterOncology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

DeuterOncology is a private, clinical-stage biotechnology company leveraging deuteration chemistry to develop improved kinase inhibitors. Its lead asset, DO-2, is a deuterated, brain-penetrant MET/RAS pathway inhibitor currently in Phase I dose expansion for MET-altered solid tumors, with preliminary data showing promising safety and activity. The company, founded by Dr. Timothy Perera, has secured Series A financing and grant funding to advance its pipeline, aiming to establish a best-in-class therapy in the competitive MET inhibitor landscape.

OncologyLung Cancer

Technology Platform

Application of deuteration (replacing hydrogen with deuterium) to improve the metabolic stability, pharmacokinetics, and therapeutic index of small molecule kinase inhibitors.

Opportunities

The significant unmet need in MET-driven NSCLC, particularly for well-tolerated, brain-penetrant therapies, presents a major opportunity.

DO-2's potential dual inhibition of MET and a RAS-pathway kinase could address resistance mechanisms and differentiate it from competitors, opening doors in combination therapy with EGFR inhibitors.

Risk Factors

Key risks include clinical failure in ongoing/ future trials, intense competition from approved and pipeline MET inhibitors, and financial dependency on raising additional capital to fund development beyond the current Phase I expansion.

Competitive Landscape

The MET inhibitor market includes approved drugs like capmatinib (Novartis) and tepotinib (Merck KGaA). DO-2 aims to compete by offering improved tolerability and pharmacokinetics via deuteration, along with potential brain penetration and a unique secondary mechanism targeting RAS-pathway resistance.

More companies in Small Molecule Drugs →More companies in Belgium →